The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes ...

Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. The Danish pharmaceutical giant said sales of Wegovy ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The Pa. Department of Environmental Protection was able to contain and cleanup an oil spill from a steel mill in Lower ...

Investigators have recovered the cockpit voice recorder of a medical transport jet that crashed Jan. 31 in Philadelphia, ...